CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Get 5 ‘Hidden Gem ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Wegovy ® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1 ...

PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS Caremark, the country's largest Pharmacy Benefit Manager (PBM) has decided that Wegovy ® (semaglutide ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare Advantage headwinds.

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template formularies, Novo said Thursday. CVS Caremark, which forms the ...